“…Nevertheless, despite not achieving the primary objectives related to significant increases in progression-free survival rates, some optimism still remained for this agent in advanced soft tissue sarcoma patients (Bailey, et al, 2006), as well as to warrant further evaluation of perifosine in combination with rituximab or other active agents in patients with relapsed/refractory Waldenstrom's macroglobulinemia (Ghobrial, et al, 2010), and with currently available therapies in renal cancer (Cho, et al, 2012). Furthermore, a number of studies have reported the potentiation of antitumor activity following combination of perifosine with distinct anticancer drugs in cancer cells derived from several types of leukemia (Nyakern, et al, 2006;Papa, et al, 2008;Tazzari, et al, 2008), multiple myeloma Hideshima, et al, 2006), osteosarcoma (Yao, et al, 2013), medulloblastoma (Kumar, et al, 2009), lung cancer (Elrod, et al, 2007), colon cancer (M. B. Chen, et al, 2012, and glioma (Momota, et al, 2005), as well as following combination of miltefosine with different anticancer compounds or treatments in distinct cancer cell types (Haberkorn, et al, 1992;Papagiannaros, et al, 2006;Spruss, et al, 1993;Thakur, et al, 2013). Thus, phase II clinical trials were conducted with…”